Sign In
Buy SUSRF
Surgical Science Sweden AB Earnings Calls
| Release date | May 20, 2026 |
| EPS estimate | $0.0321 |
| EPS actual | $0.0389 |
| EPS Surprise | 21.40% |
| Revenue estimate | 24.82M |
| Revenue actual | 24.722M |
| Revenue Surprise | -0.396% |
| Release date | Feb 19, 2026 |
| EPS estimate | $0.0729 |
| EPS actual | $0.0703 |
| EPS Surprise | -3.47% |
| Revenue estimate | 29.025M |
| Revenue actual | 29.095M |
| Revenue Surprise | 0.242% |
| Release date | Nov 13, 2025 |
| EPS estimate | $0.0752 |
| EPS actual | $0.0426 |
| EPS Surprise | -43.29% |
| Revenue estimate | 28.33M |
| Revenue actual | 28.115M |
| Revenue Surprise | -0.759% |
| Release date | Aug 21, 2025 |
| EPS estimate | $0.0779 |
| EPS actual | -$0.0411 |
| EPS Surprise | -152.81% |
| Revenue estimate | 30.105M |
| Revenue actual | 21.855M |
| Revenue Surprise | -27.41% |
Last 4 Quarters for Surgical Science Sweden AB
Below you can see how SUSRF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 21, 2025 |
| Price on release | $10.45 |
| EPS estimate | $0.0779 |
| EPS actual | -$0.0411 |
| EPS surprise | -152.81% |
| Date | Price |
|---|---|
| Aug 15, 2025 | $10.45 |
| Aug 18, 2025 | $10.45 |
| Aug 19, 2025 | $10.45 |
| Aug 20, 2025 | $10.45 |
| Aug 21, 2025 | $10.45 |
| Aug 22, 2025 | $10.45 |
| Aug 25, 2025 | $10.45 |
| Aug 26, 2025 | $10.45 |
| Aug 27, 2025 | $10.45 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Nov 13, 2025 |
| Price on release | $8.58 |
| EPS estimate | $0.0752 |
| EPS actual | $0.0426 |
| EPS surprise | -43.29% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $8.32 |
| Nov 10, 2025 | $8.53 |
| Nov 11, 2025 | $8.58 |
| Nov 12, 2025 | $8.58 |
| Nov 13, 2025 | $8.58 |
| Nov 14, 2025 | $9.95 |
| Nov 17, 2025 | $8.58 |
| Nov 18, 2025 | $8.58 |
| Nov 19, 2025 | $8.58 |
| 4 days before | 3.13% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 3.13% |
| Release date | Feb 19, 2026 |
| Price on release | $2.84 |
| EPS estimate | $0.0729 |
| EPS actual | $0.0703 |
| EPS surprise | -3.47% |
| Date | Price |
|---|---|
| Feb 12, 2026 | $2.84 |
| Feb 13, 2026 | $2.84 |
| Feb 17, 2026 | $2.84 |
| Feb 18, 2026 | $2.84 |
| Feb 19, 2026 | $2.84 |
| Feb 20, 2026 | $2.84 |
| Feb 23, 2026 | $2.84 |
| Feb 24, 2026 | $2.84 |
| Feb 25, 2026 | $2.84 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | May 20, 2026 |
| Price on release | $4.09 |
| EPS estimate | $0.0321 |
| EPS actual | $0.0389 |
| EPS surprise | 21.40% |
| Date | Price |
|---|---|
| May 13, 2026 | $2.84 |
| May 14, 2026 | $2.86 |
| May 18, 2026 | $2.86 |
| May 19, 2026 | $2.86 |
| May 20, 2026 | $4.09 |
| May 21, 2026 | $4.09 |
| May 22, 2026 | $4.00 |
| May 26, 2026 | $4.00 |
| May 27, 2026 | $4.00 |
| 4 days before | 44.01% |
| 4 days after | -2.20% |
| On release day | 0% |
| Change in period | 40.85% |
Surgical Science Sweden AB Earnings Call Transcript Summary of Q1 2026
Surgical Science reported Q1 2026 sales of SEK 236m, down 6% reported but up ~4% in local currencies after a significant USD currency headwind. Operational performance was solid: adjusted EBIT was SEK 28m (12%) — ~16% when FX-adjusted — and operating cash flow was strong at SEK 65m. Educational Products grew (6% reported, 14% in local currencies) with exceptional EMEA and UK performance; ultrasound momentum and new product launches (including shared-platform ultrasound products) were highlighted. Robotics license revenues fell year-over-year (SEK 68m vs SEK 84m) largely due to reversion to the prior commercial agreement with Intuitive after the MOU did not result in a signed deal; the company reiterates an expected SEK 60–90m negative impact on 2026 license revenues vs 2025. Management emphasized a broader, growing robotics customer base, a large long-term opportunity in simulation, continued pricing actions to protect margins, ongoing R&D and product pipeline investments, and a strategic focus on scaling production (new Tel Aviv facility expected online in Q2). The company is debt-free with SEK 668m cash, pursuing growth, potential M&A, and a planned relisting process next year.
